




RealRate

PHARMACEUTICAL 2022

Metacrine Inc
Rank 206 of 471



RealRate

The First AI Rating Agency

www.realrate.ai

The relative strengths and weaknesses of Metacrine Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Metacrine Inc compared to the market average is the variable Stockholders Equity, increasing the Economic Capital Ratio by 75% points. The greatest weakness of Metacrine Inc is the variable Comprehensive Net Income, reducing the Economic Capital Ratio by 50% points.

The company's Economic Capital Ratio, given in the ranking table, is 314%, being 39% points above the market average of 275%.

Input Variable	Value in 1000 USD
Assets, Current	78,740
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	7,760
Liabilities, Non-Current	0
Other Assets	902
Other Compr. Net Income	-6.0
Other Expenses	0
Other Liabilities	0
Other Net Income	-1,128
Other Revenues	0
Property and Equipment	347
Research and Development	45,474
Selling, General and Administrative Expense	15,605

Output Variable	Value in 1000 USD
Assets	79,989
Liabilities	7,760
Expenses	61,079
Revenues	0
Stockholders Equity	72,229
Net Income	-62,207
Comprehensive Net Income	-62,210
BaseVar	74,981
ECR before LimitedLiability	217%
Economic Capital Ratio	314%